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Proton pump inhibitors and 180-day 
mortality in the elderly after Clostridium difficile 
treatment
Evan Stuart Bradley1* , Emily Howe2, Xun Wu2 and John P. Haran1
Abstract 
Background: There is a reported association between proton pump inhibitor (PPI) exposure and increased risk of 
Clostridium difficile infection (CDI), but less is known about how this class of medications taken during treatment 
might influence mortality after CDI. Here we examine 180-day mortality rates in a cohort of CDI elders and its asso-
ciation with exposure to PPIs. We conducted a retrospective cohort study of elderly patients (> 65 years of age) 
diagnosed and treated for CDI in the years 2014–2016 (n = 874) in the Umass Memorial Health Care system, which 
represents both academic and community healthcare. Patient characteristics and medication use was extracted from 
the electronic medical record (EMR) and 6 month mortality data was obtained via the Center for Disease Control 
National Death Index. A Cox proportional hazards model was used to estimate hazard ratios associated with medica-
tion exposures and other relevant variables.
Results: Of the 874 elderly adults treated for CDI, 180-day all-cause mortality was 12.4%. Exposure to a PPI was asso-
ciated with a 55% reduced risk of mortality (adjusted hazard ratio (aHR) 0.45; 95% confidence interval (CI) 0.28–0.72). 
In our Cox model, increasing age (aHR 1.45; 95% CI 1.14–1.84), those with severe CDI infections (aHR 1.87; 95% CI 
1.22–2.88), and those with hospital acquired CDI (aHR 3.01; 95% CI 1.81–4.99) also had increased 180 day mortality 
risk. There were similar associations noted with both 90 day and 1-year mortality.
Conclusion: Use of PPIs during CDI treatment in elderly patients is associated with decreased 180-day mortality. 
Although use of PPIs has been associated with an increased risk of CDI, it appears to be protective against mortality 
when used during the treatment phase.
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Background
Clostridium difficile remains a common and costly patho-
gen. It is estimated that are around 450,000 incident cases 
of Clostridium difficile infection (CDI) in the US annually 
[1] and it incurs 1.2 to 5.9 billion dollars in direct costs to 
the health care system [2]. CDI disproportionately affects 
the elderly (65  years of age and older) [1], residents of 
nursing homes (NHs) [3], and hospitalized patients [4].
Proton pump inhibitors (PPI’s) are frequently used 
therapies in hospitalized patients for a variety of indica-
tions. PPIs have long been used as stress ulcer prophy-
laxis in critically ill patients in the intensive care unit 
(ICU) [5]. In non-critically ill patients, common indica-
tions are symptomatic gastroesophageal reflux and upper 
gastrointestinal (GI) bleeding prophylaxis for high risk 
patients, such as those on anticoagulants or long term 
non-steroidal anti-inflammatory drugs (NSAIDS) [6].
Clostridium difficile has a well-known association with 
recent antibiotic exposure [7, 8], but a variety of other 
medication have been associated with disease risk. Medi-
cations including acid reducing medications [9], corticos-
teroids [10], and antidepressants [11] are a few examples. 
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Among these, acid-reducing medications such as PPIs 
and histamine blockers (H2 blockers) have been perhaps 
the most studied. They have been implicated in increas-
ing the risk for incident infection [9, 12] as well as recur-
rent infection [13, 14]. These associations are not without 
controversy, and may reflect the fact that those treated 
with acid-reducing medications are generally more 
elderly, have more medical comorbidities, and higher risk 
for CDI independent of PPI use [15].
The effect of these medications on morbidity and mor-
tality associated with CDI is somewhat less well estab-
lished. The concurrent use of antibiotics that are high 
risk for the development of CDI has been associated with 
complications in treatment of CDI such as increased 
30 day mortality [14, 16]. There are reports that prior or 
concurrent use of acid-reducing medication have been 
associated with complications and mortality during CDI 
treatment [17–19]. It is important to note that acid-
reducing medication association with short-term compli-
cations is not consistently observed in the literature [20, 
21].
Given the relative lack data on CDI mortality risk with 
PPI exposure and its commonality as a treatment modal-
ity when a patient is hospitalized, we followed a cohort of 
incident CDI patients, treated both in the hospital and a 
an outpatient, for 6 months to determine the association 
of PPI exposure and 6 month mortality.
Methods
Study population and setting
The institutional review board at the University of Mas-
sachusetts Medical School approved this retrospective 
cohort study. The cohort of CDI-positive elderly adults 
(aged ≥ 65  years) was identified using the University of 
Massachusetts Memorial Health Care System Theradoc 
Clinical Surveillance Software System (Premier, Inc., 
Charlotte, NC). Using this system, we constructed a 
cohort of elderly adults with positive C. difficile toxin B 
polymerase chain reaction (PCR) diarrheal stool samples 
between 2012 and 2014 whom had initially presented 
to either academic and community hospital setting. 
Both inpatient and outpatient treatment settings were 
included. We confirmed that the incident case toxin test 
was done on a diarrheal stool sample and that the indi-
vidual was treated for a CDI after the positive test was 
reported.
Data extraction
To reduce the potential for systematic error and to miti-
gate bias, we followed protocols for the optimal conduct 
of retrospective studies. Before data were abstracted, we 
a priori defined the pertinent predictor and outcome 
variables to be extracted from the medical record in a 
standardized manner. Trained abstractors used a stand-
ardized collection form to query the EMR to obtain lon-
gitudinal data pertaining medication use prior to and 
during treatment for CDI. Demographic data, includ-
ing age at CDI diagnosis, sex, race and ethnicity, were 
collected. We also calculated a Charlson comorbidity 
index (CCI) score to characterize the individual’s medi-
cal comorbidities. Details of the initial CDI treatment, 
including if the case of CDI was hospital acquired, and 
the patient received dual antibiotic coverage were also 
collected. We defined the initial CDI as severe by using 
both the Infectious Disease Society of America (IDSA) 
2010 clinical practice guidelines (i.e. presence of leu-
kocytosis greater then 15,000, serum creatinine 1.5× 
greater then baseline, hypotension, shock, megacolon, 
ileus or need for surgical intervention), or if the treating 
physician felt the case was severe and escalated therapy. 
Abstractors were blinded to outcome status and mortal-
ity data was obtained after all patients in the cohort had 
their data extraction complete. These methods were used 
to reduce information bias during clinical record review.
Classification of drug exposures and mortality
We used the EMR to determine the medications each 
participant was exposed to. We specifically queried the 
EMR for medication exposures initiated during treat-
ment for CDI. We had particular interest in antibiot-
ics (both those used in the treatment of CDI and those 
used to treat other bacterial infections) and acid reducing 
medications. Data on both prevalent (daily medication 
use prior to CDI) and incident acid-reducing medication 
use (initiated during treatment for CDI) including both 
PPIs and H2 blocker medications were collected.
To determine mortality outcomes, patients in our 
cohort were queried in the Center for Disease Control 
National Death Index (NDI). Six-month all-cause mor-
tality was determined for each individual CDI case. Only 
after all study information was collected for all partici-
pants did two independent physician reviewers (JH, EB) 
make case and control assignments. We performed this 
same procedure for both 90-day and 1-year mortality.
Data analysis
We used Chi-square tests to compare categorical vari-
ables and the student’s t-test for continuous variables 
between CDI patients with 180-day mortality and sur-
vivors. Bivariate risk ratios were determined by logistic 
regression. After examining the proportional hazards 
assumption for Cox proportional hazards model, it 
was determined that the variables did not violate the 
model’s assumptions and the Cox model was used to 
identify associations between predictor variables and 
the outcome of 180-day mortality. Clinically important 
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treatment factors included antibiotic treatment dur-
ing initial CDI treatment, acid-reducing PPI medication 
exposure, and probiotic treatment. The other main vari-
ables of interest included patient demographic character-
istics (including age, sex, race), infection characteristics 
that included hospital acquired CDI and IDSA defined 
severe CDI, location of residence (community or nursing 
home), and medical comorbidities using the CCI score. 
The final adjusted model included clinically important 
variables we defined a priori and variables associated 
with the outcome at a significance level of p < 0.10 from 
our bivariate analysis. Kaplan–Meier survival analysis 
was used to determine time to all cause mortality. The log 
rank test was used to compare the survival curves of time 
to mortality. Significance was set at a p value < 0.05 for all 
analysis. We used multiple imputation to address missing 
data, after exploring the data and determining missing 
data was missing at random. We used Stata version 13.1 
for all analyses (Stata Corp LP, College Station, TX).
Results
During the 3-year study period from 2012 to 2014, there 
were a total of 874 positive C. difficile PCR results for 
which treatment data was available. Of this group, 109 
(12.47%) died within 180  days of CDI diagnosis. The 
demographic and medical comorbidity data comparing 
the two groups are shown in Table 1.
Patients with greater 180-day mortality were older, with 
higher CCI scores and lived in a nursing home setting. 
Patients with a prior diagnosis of CDI did not appear 
to suffer increased mortality as a result of treatment for 
recurrent disease. There were some notable differences 
among those that died and different treatment charac-
teristics (Table 2). Patients were more likely to die if they 
had a hospital acquired CDI (risk ratio [RR] of 3.69; 95% 
confidence interval (CI) 2.45 to 5.37) and severe CDI 
infection type (RR of 1.68; 95% CI 1.13 to 2.41). A lower 
prevalence of oral metronidazole use and higher preva-
lence of oral vancomycin use was observed in patients 
who did suffer 180  day mortality, but this may reflect 
that fact that oral metronidazole as a solo agent is gener-
ally reserved for uncomplicated cases while more severe 
cases are treated with oral vancomycin. The dosages of 
these antibiotics were standard for adult patients being 
treated for this condition (metronidazole 500  mg TID 
and vancomycin 250 mg QID). Patients that either con-
tinued PPI use or were started on a PPI during the index 
CDI were 51% less likely to die within 6 months (RR 0.49; 
95% CI 0.31 to 0.75). There were no observed differences 
in those exposed to a H2 blocker or corticosteroid how-
ever a lower prevalence of death was seen among patients 
given a concurrent probiotic.
The results from our Cox model are shown in Table 3. 
After adjusting for the other covariates of interest, expo-
sure to PPI reduced the risk of 180-day mortality by 55% 
(adjusted hazard ratio (aHR) 0.45; 95% CI 0.28–0.72). The 
risk of death was not significant for probiotic or for other 
non-CDI treatment antibiotic exposures in the model. In 
addition to 180-day mortality we also ran the Cox model 
looking at 90-day and 1-year mortality. In these models 
PPIs also reduced both 90-day (aHR 0.33; 95% CI 0.19–
0.59) and 1-year mortality (aHR 0.51; 95% CI 0.35–0.77) 
Table 1 Characteristics of study patients
Data is presented as n (percentages) unless otherwise indicated
CCI: Charlson comorbidity index
Demographics Survivors (765) Died (109) p value
n % n %
Age (SD) 76.5 (8.1) 78.4 (8.2) 0.018
Female 447 (58.4) 63 (57.8) 0.90
White 690 (90.2) 96 (88.1) 0.49
Hispanic 37 (4.8) 1 (9.2) 0.06
African American 19 (2.5) 7 (6.4) 0.024
Asian 3 (0.4) 1 (0.9) 0.45
Nursing home 102 (13.3) 28 (25.7) 0.004
Medical history
 CCI 0 148 (19.3) 7 (6.4) 0.001
 CCI 1 124 (16.2) 15 (13.8) 0.51
 CCI 2 135 (17.6) 22 (20.2) 0.52
 CCI 3 or more 358 (46.8) 65 (59.6) 0.012
 Immunosuppressed 59 (7.7) 8 (7.3) 0.11
 Diabetic 256 (33.5) 45 (41.3) 0.89
 Prior CDI diagnosis 199 (26.0) 27 (24.8) 0.78
Table 2 Treatment characteristics
Data are presented as n (percentages) unless otherwise indicated
IV: intravenous; PPI: proton pump inhibitor; H2 blocker: H2 receptor antagonist
Type Survivors (765) Died (109) p value
n % n %
Severe infection 126 (16.5) 29 (26.6) 0.010
Hospital acquired 365 (47.7) 87 (79.8) < 0.001
Antibiotic regimens
 IV Flagyl 147 (19.2) 33 (30.3) 0.008
 Oral Flagyl 355 (46.4) 31 (28.4) < 0.001
 Oral Vanco 360 (47.1) 63 (57.8) 0.036
 Combo 87 (11.4) 13 (11.9) 0.87
 Bacterial other 335 (43.8) 72 (66.1) < 0.001
Other medications
 PPI 296 (38.7) 24 (22.0) 0.001
 H2 blocker 46 (6.0) 4 (3.7) 0.41
 Corticosteroids 75 (9.8) 7 (6.4) 0.26
 Probiotic 54 (7.1) 1 (0.9) 0.014
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without much change to any of the other variables esti-
mates. The PPI used in this cohort was most frequently 
pantoprazole (70% of cases). There was no difference in 
mortality benefit depending on which PPI was used. The 
mortality benefit was similar for patients that had been 
on PPIs at the time of CDI treatment and patients that 
had PPI treatment initiated at time of CDI treatment, 
so in our final analysis, we did not differentiate between 
prevalent and incident PPI exposure.
Concerning the other covariates in the Cox model, the 
risk of death increased by age with a 45% increase risk 
every 10  years starting at the age of 65  years (Table  3). 
Patients with higher CCI scores, severe infection type, 
and a hospital-acquired infection also had significantly 
increased mortality risk. Gender and home living envi-
ronment did not reach statistical significance.
Our Kaplan–Meier survival curves (Fig. 1) demonstrate 
that among patients with severe and non-severe CDI 
types, exposure to PPIs conferred a survival benefit.
Discussion
Although PPI may be a risk factor for CDI recurrence, 
especially with long term use [14], our finding suggest 
that its use in the treatment phase may be beneficial. PPIs 
may benefit patients when used acutely in the setting of 
CDI, although long term they may influence recurrence. 
This finding should help inform further research regard-
ing the influence of PPI on the clinical course of CDI and 
whether it is appropriate to initiate or maintain PPI treat-
ment when a patient is being treated for CDI and when to 
discontinue it after CDI treatment.
Mechanism for reduced mortality with PPIs in CDI
Exposure to PPIs during the treatment course of CDI 
may help reduce intestinal inflammation. In  vitro, 
neutrophils stimulated by Helicobacter pylori extracts 
that were treated with omeprazole or lansoprazole 
showed decreased expression of endothelial attachment 
factors, an effect not seen when the same neutrophils 
were treated with famotidine or ranitidine [22]. This data 
suggests PPIs may have an anti-inflammatory effect by 
preventing migration of neutrophils into tissue. Another 
in  vitro study showed that coloncyte cultures grown in 
the presence of omeprazole showed some notable gene 
expression changes including down-regulation of a pro-
tein involved in leukocyte tissue transmigration and 
down-regulation of a C. difficile toxin target [23]. These 
changes in in vitro gene expression can be both hypoth-
esized to promote or inhibit infection and inflamma-
tion. Changes in host and pathogen gene expression after 
exposure to PPIs may alter the natural disease course, 
however human evidence is lacking.
Another hypothesized mechanism through which 
acid-reducing medication could effect the course of 
CDI is through changes in colonic flora, which has been 
observed with PPI treatment [9, 24]. The effect of PPI in 
this setting has not been well studied and how the altered 
colonic flora after PPI exposure might influence the 
course CDI is not known.
In this article, we report a decrease in all-cause mor-
tality in patients treated for CDI who were also treated 
with PPI, we did not assess the effect of PPI on mortal-
ity specifically related to CDI. As such, it may be that the 
effect PPI has on mortality in CDI patients may also be 
independent of any direct effect of the disease itself. PPI 
remains an effective treatment for certain conditions, 
such as patients hospitalized with upper GI bleeding or 
Table 3 Cox regression model
CCI: Charlson comorbidity index; PPI: proton pump inhibitor
Mortality by 6 months p-values
Hazard ratio 95% CI
Age/10 years 1.45 (1.14–1.84) 0.002
Hispanic 0.17 (0.03–1.26) 0.08
African American 1.82 (0.83–4.01) 0.14
Nursing home 1.27 (0.81–2.00) 0.29
CCI score 1.18 (1.09–1.29) < 0.001
Severe infection 1.87 (1.22–2.88) 0.004
Hospital acquired 3.01 (1.81–4.99) < 0.001
Bacterial other 1.45 (0.94–2.23) 0.09
PPI 0.45 (0.28–0.72) 0.005
Probiotic 0.19 (0.03–1.36) 0.10 Fig. 1 Kaplan–Meier survival curves for patients patient groups 
treated with and without PPI. Solid lines represent patients who were 
treated with PPI during CDI treatment, dashed lines represent those 
who were not. Grey lines represent patients who suffered from severe 
CDI, black lines are CDI cases without severe features. PPI: proton 
pump inhibitor; CDI: Clostridium difficile infection; svCDI: severe 
Clostridium difficile infection
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those critically ill in the ICU [5]. In these patients the 
usual barriers that protect the gastric mucosa, such as 
mucous or bicarbonate secretion, have broken down and 
PPIs limit proton secretion from undamaged mucosa, 
leading to increased gastric pH that limits direct dam-
age to mucosa from acidic environment and also reduces 
pepsin activation which enzymatically degrade damaged 
mucosa or fibrin clots that may have formed [25]. It may 
be that patients with CDI are also at risk for stress ulcers 
or other conditions treated effectively by PPI and this is 
the reason for the observed mortality benefit.
PPIs and all-cause mortality
In patients hospitalized for other medical reasons, data 
exist to show that PPIs are effective prophylactically to 
prevent upper GI bleeding for those at high risk, such as 
critically ill patients [5]. However, acid-reducing medica-
tion does not appear to generally benefit all hospitalized 
patients. PPI use has been associated with increases in 
all cause mortality after hospitalization for myocardial 
infarction [26] and when used in long-term in hemodi-
alysis patients [27]. It is clear that PPI does not generally 
lead to decreased mortality and only benefits patients 
with certain conditions, of which CDI may be one.
Controversy over CDI and PPIs
The risk of developing CDI has been well linked to PPIs 
use. It has been hypothesized that the association is due 
to the nature of patients treated with PPI who are gen-
erally more elderly and have more medical comorbidi-
ties and this are at a higher risk for CDI in general. In 
2014, Novack et al. attempted to address this concern by 
performing a case control study in which controls were 
patients suspected of having CDI, but with negative test-
ing, as opposed to other matching methodologies. They 
reported that use of PPI use was associated with a nega-
tive test as opposed to increased risk [15]. Other stud-
ies that compare CDI patients to those that were tested 
but were negative also fail to find an association between 
PPI use and CDI [28, 29]. In a prospective cohort of 
894 cases of CDI inpatients showed there was no asso-
ciation between concurrent PPI use and risk of recurrent 
CDI [30]. The same group evaluated use of PPIs in ICU 
patients and the risk of developing CDI and also found 
no association [31].
The association between PPI use and severity of CDI 
and mortality after CDI treatment not been thoroughly 
investigated. There are some reports that cases of CDI 
associated with PPI use are more severe and lead to 
higher complication rates and mortality [17–19]. This 
could be explained by the average patient treated with 
PPIs being generally older and having more medical 
comorbidities. One study that attempted to address this 
specific concern followed 285 patients treated for CDI 
at Mayo Clinic found that after adjustment for age and 
medical comorbidities, CDI patients with PPI exposure 
were not more likely to suffer complications or be associ-
ated with treatment failure [20]. Although these authors 
did not note a protective effect, all cause mortality in 
these patients was not explored. In a meta analysis evalu-
ating risk factors for poor outcomes in patients treated 
for CDI, PPI was associated with increased mortality in 
a single study out of the 40 studies included in the analy-
sis [14]. This systematic review found that most studies 
evaluating mortality failed to find an association. Here 
we report a positive association with PPI use and reduced 
mortality even after multivariate adjustment.
H2 blockers and mortality
H2 blockers and PPIs are both used to suppress gastric 
acid production and are typically used for similar indica-
tions. Prior studies have found that H2 blockers and PPI 
similarly affect CDI risk and recurrence [13, 32]. In stud-
ies evaluating severity of CDI in the setting of gastric acid 
suppression these agents have been typically analyzed 
together as representing a similar exposure [14, 17] and 
the specific contribution of H2 blockers has not been 
reported. In our analysis, treatment with H2 blockers 
did not confer a similar mortality benefit to PPI. These 
medications act by different mechanisms, and it may be 
that the mortality benefit seen in PPI use is not related 
specifically to gastric acid suppression. Alternatively, the 
efficacy of the gastric acid blockade is typically thought 
to be greater in PPIs then in H2 blockers [33], and hence, 
it may be that the mortality benefit results from a more 
robust acid blockade in PPIs.
Other covariates and mortality risk
Other factors contributing to mortality in our data 
set included increasing age, higher CCI score, hospi-
tal acquired CDI and severe or complicated infection 
as determined by 2010 IDSA guidelines. The finding of 
increased mortality related to advancing age and severe 
infection was seen among most studies in a 2014 meta 
analysis looking at outcomes of CDI and makes intuitive 
sense [14]. The association with higher CCI score with 
30 day mortality was also reported in two of the studies 
included in that analysis [14]. In our analysis, it was sig-
nificantly associated with 180-day mortality, suggesting 
that these patients are particularly high risk and require 
close attention when CDI develops during the hospital 
course. The use antibiotics during CDI treatment was 
seen to increase risk of complication [14], however, this 
did not appear to effect mortality in our study.
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Strengths and limitations
Our study found a decrease in mortality associated 
with PPI use that was consistent and seen at 90-days, 
6 months and 1 year, suggesting a lasting benefit associ-
ated with these medications. All CDI cases in the study 
period were included, which should limit referral bias. 
Our study included both patients treated within the hos-
pital and at home and looked beyond inpatient morbid-
ity and mortality. Taken together our study suggests PPIs 
may play a beneficial role in reducing death when taken 
during CDI treatment.
However, all-cause mortality was measured, not mor-
tality related specifically incident or recurrent CDI. 
We also did not collect data on other outcomes associ-
ated with CDI treatment such as hospital length of stay, 
recurrences, or treatment complications. Although the 
mortality benefit appears robust, how the use of PPI 
affects the clinical course of CDI remains to be studied 
in depth. Additionally our investigation was a retrospec-
tive cohort study design, which may introduce selection 
and information biases. We attempted to limit this bias 
by applying standard protocols for the optimal conduct 
of retrospective study.
Conclusion
Here we report a decrease in all cause mortality at 180-
days as well as 90-days and 1-year in patients treated for 
CDI who are concomitantly treated with a PPI. Although 
PPI may be a risk factor for CDI recurrence, especially 
with long term use [14], our finding suggest that its use in 
the treatment phase may be beneficial. It is possible that 
the reported effects of PPI on immune function [22] or 
coloncyte gene expression [23] in the acute phase of CDI 
reduce the severity of the disease leading to decreased 
mortality. Although it is clear that PPIs are generally over 
used in hospitalized patients, and patients stay on these 
medications long term after discharge [34], PPIs may 
benefit patients when used acutely in the setting of CDI. 
This finding should help inform further research regard-
ing the influence of PPI on the clinical course of CDI and 
whether it is appropriate to initiate or maintain PPI treat-
ment when a patient is being treated for CDI and when to 
discontinue it after CDI treatment.
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